Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer.

ABSTRACT: The mainstay treatment for patients with immediate resectable pancreatic cancer remains upfront surgery, which represents the only potentially curative strategy. Nevertheless, the majority of patients surgically resected for pancreatic cancer experiences disease relapse, even when a combination adjuvant therapy is offered. Therefore, aiming at improving disease free survival and overall survival of these patients, there is an increasing interest in evaluating the activity and efficacy of neoadjuvant and perioperative treatments. In this view, it is of utmost importance to find biomarkers able to select patients who may benefit from a preoperative therapy rather than upfront surgical resection. Defined genomic alterations and a dynamic inflammatory microenvironment are the major culprits fo

SUBMITTER: Merz V 

PROVIDER: S-EPMC9114435 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature